NSAID-Induced Acute Phase Response is Due to Increased Intestinal Permeability and Characterized by Early and Consistent Alterations in Hepatic Gene Expression

Toxicologic Pathology - Tập 34 Số 2 - Trang 168-179 - 2006
Stuart Tugendreich1, Cecelia I. Pearson1, John E. Sagartz2, Kurt Jarnagin1, Kyle L. Kolaja1
1Iconix Pharmaceuticals Inc., Mountain View, California 94043, USA.
2Seventh Wave Laboratories, LLC, Chesterfield, Missouri 63005, USA

Tóm tắt

Toxicogenomics using a reference database can provide a better understanding and prediction of toxicity, largely by creating biomarkers that tie gene expression to actual pathology events. During the course of building a toxicogenomic database, an observation was made that a number of non-steroidal anti-inflammatory compounds (NSAIDs) at supra-pharmacologic doses induced an acute phase response (APR) and displayed hepatic gene expression patterns similar to that of intravenous lipopolysaccharide (LPS). Since NSAIDs are known to cause injury along the gastrointestinal tract, it has been suggested that NSAIDs increase intestinal permeability, allowing LPS and/or bacteria into the systemic circulation and stimulating an APR detectable in the liver. A short term study was subsequently conducted examining the effects of aspirin, indomethacin, ibuprofen, and rofecoxib to rats and a variety of endpoints were examined that included serum levels of inflammatory cytokines, histologic evaluation, and hepatic gene expression. Both indomethacin and ibuprofen injured the gastrointestinal tract, induced an APR, and increased serum levels of LPS, while rofecoxib and aspirin did not affect the GI tract or induce an APR. In treatments that eventually showed a systemic inflammatory response, hepatic expression of many inflammatory genes was noted as early as 6 hours after treatment well before alterations in traditional clinical pathology markers were detected. This finding led to the creation of a hepatic gene expression biomarker of APR that was effectively shown to be an early identifier of imminent inflammatory injury. In terms of the relative gastrointestinal safety and the NSAIDs studied, an important safety distinction can be made between the presumptive efficacious dose and the APR-inducing dose for indomethacin (1—2-fold), ibuprofen (5-fold), and rofecoxib (~250-fold). Our data support the notion that NSAID-induced intestinal injury results in leakage of commensural bacteria and/or LPS into the circulation, provoking a systemic inflammatory response and that hepatic gene expression-based biomarkers can be used as early and sensitive biomarkers of APR onset. [The table referenced in this paper is not printed in this issue of Toxicologic Pathology. It is available as a downloadable text file in the online edition of Toxicologic Pathology, 34(2). In order to access the full article online, you must have either an individual subscription or a member subscription accessed through www.toxpath.org .]

Từ khóa


Tài liệu tham khảo

10.1016/S0300-483X(02)00481-X

10.1038/sj.bjp.0701968

Blake GJ, 2001, Ital Heart J, 2, 796

10.1056/NEJM200011233432103

10.1517/14740338.4.3.491

10.1016/S1532-0464(02)00525-7

EsserAFChapmanDBiological Membranes1982IVLondonAcademic Press277327

10.2165/00129785-200505030-00003

10.1054/clnu.2001.0438

10.1016/j.jbiotec.2005.03.022

10.1016/S1097-2765(02)00708-6

10.1021/bi992215v

10.1093/toxsci/67.2.232

10.1093/toxsci/67.2.219

10.1136/gut.50.suppl_3.iii25

10.1002/1529-0131(200002)43:2<370::AID-ANR17>3.0.CO;2-D

Hirschowitz BI, 1994, Gastroenterologist, 2, 207

10.2131/jts.26.95

10.2131/jts.26.103

10.1046/j.1365-2125.2003.01934.x

Kaysen GA, 1998, J Am Soc Nephrol, 9, 2368, 10.1681/ASN.V9122368

10.1007/BF00320521

10.1046/j.1365-2044.1998.00438.x

10.1053/sarh.2002.37217

10.1016/S0016-5085(99)70334-3

Laney DW, 1994, Am J Physiol, 266, G899

10.2165/00002018-200427060-00005

10.1053/jhep.2000.19621

10.1046/j.1365-2036.2003.01454.x

10.1007/BF01893017

10.1101/gr.2807605

10.1007/BF00916401

Pronai L, 2003, Int J Immunopathol Pharmacol, 16, 23

Riendeau D, 2001, J Pharmacol Exp Ther, 296, 558

10.1007/s000110050338

10.1124/jpet.102.041624

10.1016/j.taap.2005.05.008

10.1093/alcalc/37.1.81

10.1111/j.1749-6632.1989.tb24000.x

10.1007/s11883-004-0102-x

10.1016/S0021-9258(18)67560-X

10.1136/gut.49.5.650

10.1289/ehp.7036

Takeuchi K, 2003, J Physiol Pharmacol, 4, 165

10.1124/jpet.102.041715

10.1124/jpet.300.3.754

10.1007/BF00920471

10.1016/S1097-2765(02)00710-4

10.1152/ajprenal.00008.2003

10.1073/pnas.0336385100

Thông tin
Thông tin xuất bản

Toxicologic Pathology

Tập 34 Số 2

168-179

Thông tin tác giả